SCHEMBL19917138

SCHEMBL19917138

CC1=C(C(=O)OCc2ccccc2)CC(F)(F)CC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.46
TDP1 Q9NUW8 3/20 0.45
SLC6A2 P23975 1/20 0.45
SLC6A3 Q01959 1/20 0.45
KMT2A Q03164 1/20 0.45
CHRM2 P08172 1/20 0.43
CHRM4 P08173 1/20 0.43
CHRM5 P08912 1/20 0.43
CHRM1 P11229 1/20 0.43
CHRM3 P20309 1/20 0.43
LMNA P02545 1/20 0.42
MAPT P10636 2/20 0.41
HPGD P15428 1/20 0.41
DDB1 Q16531 1/20 0.40
CRBN Q96SW2 1/20 0.40
MAPK1 P28482 2/20 0.40
TSHR P16473 2/20 0.40
CYP3A4 P08684 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
GPBAR1 Q8TDU6 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21159639 0.87 CHRM5 (0.44) ALDH1A1TDP1CHRM2CHRM4CHRM5
SCHEMBL21057532 0.80 ALDH1A1 (0.39) ALDH1A1TDP1SLC6A2SLC6A3KMT2A
SCHEMBL21138207 0.77 TDP1 (0.53) ALDH1A1TDP1SLC6A2SLC6A3KMT2A
SCHEMBL3623581 0.76 TDP1 (0.47) ALDH1A1TDP1SLC6A2SLC6A3KMT2A
SCHEMBL12987954 0.74 CASP3 (0.49) ALDH1A1TDP1KMT2ALMNAMAPT
SCHEMBL19917161 0.72 CYP3A4 (0.45) ALDH1A1TDP1SLC6A2SLC6A3KMT2A
SCHEMBL11262327 0.72 KMT2A (0.60) ALDH1A1TDP1SLC6A2SLC6A3KMT2A
SCHEMBL22581437 0.71 TDP1 (0.45) ALDH1A1TDP1SLC6A2SLC6A3KMT2A
SCHEMBL19917163 0.71 GPBAR1 (0.43) ALDH1A1TDP1SLC6A2SLC6A3KMT2A
SCHEMBL24117922 0.70 TDP1 (0.54) ALDH1A1TDP1SLC6A2SLC6A3KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3505171-A1 BICYCLIC NITROGENATED HETEROCYCLIC COMPOUND Mitsubishi Tanabe Pharma Corporation (JP) 2019-07-03 EP disclosed
EP-3505171-A1 BICYCLIC NITROGENATED HETEROCYCLIC COMPOUND Mitsubishi Tanabe Pharma Corporation (JP) 2019-07-03 EP disclosed
US-20190185479-A1 BICYCLIC NITROGENATED HETEROCYCLIC COMPOUND MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-06-20 US disclosed
US-20190185479-A1 BICYCLIC NITROGENATED HETEROCYCLIC COMPOUND MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-06-20 US disclosed
WO-2018038265-A1 BICYCLIC NITROGENATED HETEROCYCLIC COMPOUND 田辺三菱製薬株式会社 2018-03-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190185479-A1 BICYCLIC NITROGENATED HETEROCYCLIC COMPOUND PDE7B, PDE3A, PDE7A ALDH1A1 1644/4885TDP1 392/4885SLC6A2 1243/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.